Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Repositioning PARP inhibitors for SARS‐CoV‐2 infection(COVID‐19); a new multi‐pronged therapy for acute respiratory distress syndrome?
Nicola J. Curtin, Krisztiàn Bányai, James Thaventhiran, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 16, pp. 3635-3645
Open Access | Times Cited: 62

Showing 26-50 of 62 citing articles:

NAD+ Degrading Enzymes, Evidence for Roles During Infection
Arnold Tan, Craig Doig
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 18
Involvement of epigenetics in affecting host immunity during SARS-CoV-2 infection
Assirbad Behura, Lincoln Naik, Salina Patel, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2022) Vol. 1869, Iss. 3, pp. 166634-166634
Open Access | Times Cited: 13
Therapeutic Significance of microRNA-Mediated Regulation of PARP-1 in SARS-CoV-2 Infection
Sabyasachi Dash, Chandravanu Dash, Jui Pandhare
Non-Coding RNA (2021) Vol. 7, Iss. 4, pp. 60-60
Open Access | Times Cited: 16
Inhibition of PARP1 improves cardiac function after myocardial infarction via up-regulated NLRC5
Jiaming Luo, Hongbin Lin, Ya-Qian Weng, et al.
Chemico-Biological Interactions (2024) Vol. 395, pp. 111010-111010
Closed Access | Times Cited: 2
Repurposing and computational design of PARP inhibitors as SARS-CoV-2 inhibitors
Shailima Rampogu, Tae Sung Jung, Min Woo Ha, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 6
Antiviral mechanisms of sorafenib against foot-and-mouth disease virus via c-RAF and AKT/PI3K pathways
Sirin Theerawatanasirikul, Varanya Lueangaramkul, Ploypailin Semkum, et al.
Veterinary Research Communications (2023) Vol. 48, Iss. 1, pp. 329-343
Closed Access | Times Cited: 6
COVID-19: A Challenge to Physiology of Aging
Aleksei G. Golubev
Frontiers in Physiology (2020) Vol. 11
Open Access | Times Cited: 16
Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
Michalis Liontos, Evangelos Terpos, Christos Markellos, et al.
Vaccines (2021) Vol. 9, Iss. 10, pp. 1148-1148
Open Access | Times Cited: 14
PARP2 poly(ADP-ribosyl)ates nuclear factor erythroid 2-related factor 2 (NRF2) affecting NRF2 subcellular localization
L Jankó, Emese Tóth, Miklós Laczik, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
The Potential Association Between PARP14 and SARS-CoV-2 Infection (COVID-19)
Amanda L Tauber, Stephanie S. Schweiker, Stephan M. Levonis
Future Medicinal Chemistry (2021) Vol. 13, Iss. 6, pp. 587-592
Open Access | Times Cited: 12
It Is Time for an Oil Change: Polyunsaturated Fatty Acids and Human Health.
Natalie Powell, Suman Chaudhary, Asma Zaidi
PubMed (2021) Vol. 118, Iss. 5, pp. 426-430
Closed Access | Times Cited: 11
The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection
Dimitra Ioanna Lampropoulou, Vanessa-Meletia Bala, Eleni Zerva, et al.
The Journal of Infection in Developing Countries (2022) Vol. 16, Iss. 01, pp. 101-111
Open Access | Times Cited: 8
Emerging Treatment Approaches for COVID-19 Infection: A Critical Review
Alok Bharadwaj, Rasanpreet Kaur, Saurabh Gupta
Current Molecular Medicine (2023) Vol. 24, Iss. 4, pp. 435-448
Closed Access | Times Cited: 4
Clinical and radiological pattern of olaparib-induced interstitial lung disease
Alexandre Brudon, Dorine Fournier, Frédèric Selle, et al.
BMC Pulmonary Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Oncology Drug Repurposing for Sepsis Treatment
Izabela Rumieńczyk, Maria Kulecka, Małgorzata Statkiewicz, et al.
Biomedicines (2022) Vol. 10, Iss. 4, pp. 921-921
Open Access | Times Cited: 7
Insights into the modulation of the interferon response and NAD+in the context of COVID-19
Nada J. Habeichi, Cynthia Tannous, Andriy Yabluchanskiy, et al.
International Reviews of Immunology (2021) Vol. 41, Iss. 4, pp. 464-474
Closed Access | Times Cited: 9
Potential Drugs Against COVID-19 Revealed By Gene Expression profile, Molecular Docking and Molecular Dynamic Simulation
Claudia Cava, Gloria Bertoli, Isabella Castiglioni
Future Virology (2021) Vol. 16, Iss. 8, pp. 527-542
Open Access | Times Cited: 8
Triple-Negative Breast Cancer and the COVID-19 Pandemic: Clinical Management Perspectives and Potential Consequences of Infection
Justin M. Brown, Marie‐Claire D. Wasson, Paola Marcato
Cancers (2021) Vol. 13, Iss. 2, pp. 296-296
Open Access | Times Cited: 8
A narrative review of COVID-19-related acute respiratory distress syndrome (CARDS): “typical” or “atypical” ARDS?
Dan Pu, Xiaoqian Zhai, Yuwen Zhou, et al.
Annals of Translational Medicine (2022) Vol. 10, Iss. 16, pp. 908-908
Open Access | Times Cited: 6
A Review on Dietary Additive, Food Supplement and Exercise Effects on the Prevention of Covid-19
Amirhossein Abedini, Aida Malek Mahdavi, Adel Mirza Alizadeh, et al.
Nutrition and Food Sciences Research (2022) Vol. 9, Iss. 1, pp. 1-14
Closed Access | Times Cited: 5
Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19
Sara Schumann, Astrid Kaiser, Ferdinando Nicoletti, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8803-8803
Open Access | Times Cited: 7
PARP in the neuropathogenesis of cytomegalovirus infection – Possible role and therapeutic perspective
Sathish Sankar, D. Vasanth, Govindasamy Rajakumar
Microbial Pathogenesis (2023) Vol. 176, pp. 106018-106018
Closed Access | Times Cited: 2
Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome
Simon Bossart, S. Morteza Seyed Jafari, Kristine Heidemeyer, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 2
PARP-inhibitors in a non‐oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open
Ettore Capoluongo
Biomedicine & Pharmacotherapy (2020) Vol. 130, pp. 110536-110536
Open Access | Times Cited: 5
Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey
Raffaella Cioffi, G. Sabetta, Emanuela Rabaiotti, et al.
International Journal of Gynecological Cancer (2021) Vol. 31, Iss. 10, pp. 1363-1368
Open Access | Times Cited: 5

Scroll to top